USound and Partners to Deliver Next-Generation Over-the-Counter Hearing Aid

USound, a leading provider of advanced audio solutions, announced today its collaboration with partners to develop and deliver a reference design for a cutting-edge over-the-counter (OTC) hearing aid. The reference design will integrate USound’s newest Kore 4.0 audio module, ASE’s Micro SiP (System-in-Package), and OBO Pro2’s innovative hearing aid design, delivering the most advanced hearing aid in the market.

The partnership combines the strengths of all three companies. USound’s expertise in advanced audio technology and its newest Kore 4.0 module will ensure superior sound quality and performance. ASE Chung-Li provides the most compact Bluetooth Micro SiP, designed specifically for the hearable devices; OBO Pro2, an experienced hearing aid manufacturer, delivers the OTC hearing aid and integrates all components into a sleek and user-friendly device.

“We are thrilled to partner with OBO Pro2 and ASE Chung-Li to create a state-of-the-art over-the-counter hearing aid that meets the needs of millions of people suffering from hearing loss worldwide,” said Ferruccio Bottoni, CEO of USound. “Our Kore 4.0 module combined with ASE’s latest Bluetooth Micro SiP provides a superior audio experience, while OBO Pro2’s expertise in hearing aid design ensures that the device is easy to use and comfortable to wear.”

The reference design enables hearing aid manufacturers to rapidly develop and produce OTC hearing aids that meet the highest standards of performance and reliability. With an estimated 500 million people worldwide suffering from hearing loss, the market for OTC hearing will grow significantly in the coming years.

“Collaborating with Usound that embedded ASE’s Micro SiP to provide a high-quality and reliable hearing aid solution to our customers,” said the CEO of OBO Pro2. “We believe that our expertise in hearing aid design combined with USound’s advanced audio technology will enable us to deliver a superior product that will make a positive impact on people’s lives.”

The reference design will be available to hearing aid manufacturers in the second half of 2023.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version